See more : Taiwan Environment Scientific Co., Ltd. (8476.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Mega Lifesciences Public Company Limited (MEGA-R.BK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mega Lifesciences Public Company Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- China Television Media, Ltd. (600088.SS) Income Statement Analysis – Financial Results
- Food and Drinks Public Company Limited (F&D.BK) Income Statement Analysis – Financial Results
- Nishoku Technology Inc. (3679.TW) Income Statement Analysis – Financial Results
- Val-d’Or Mining Corporation (VZZ.V) Income Statement Analysis – Financial Results
- Filament Health Corp. (FH.NE) Income Statement Analysis – Financial Results
Mega Lifesciences Public Company Limited (MEGA-R.BK)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.megawecare.com
About Mega Lifesciences Public Company Limited
Mega Lifesciences Public Company Limited, together with its subsidiaries, manufactures, markets, and sells health food supplements, prescription pharmaceutical products, over-the-counter (OTC) products, herbal products, vitamins, and fast moving consumer goods. The company operates through Brands, Distribution, and Original Equipment Manufacture segments. It provides various complementary medicines for bone and joint, children, diabetic, heart, herbal, liver and digestive, skin, slimming, and well-being care, as well as men's and women's care products and sports supplements; gastrointestinal and pain care OTC medicines; and prescription medicines in the areas of iron supplement, anticoagulant, diabetology, cardiology, dermatology, gastroenterology, neurology, pain, osteoporosis, respiratory, urology, oncology, and nephrology. The company also offers logistical and marketing services for the sale of goods manufactured by third parties. In addition, the company engages in the operation of wellness center; and software design, development, and other services business. It operates in the Asia Pacific, the Middle East, Africa, and the Commonwealth of Independent States. The company was incorporated in 1982 and is headquartered in Bangkok, Thailand. Mega Lifesciences Public Company Limited is a subsidiary of Unistretch Limited.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15.68B | 15.69B | 14.14B | 12.59B | 11.13B | 10.34B | 9.60B | 8.81B | 7.94B | 7.73B | 7.03B | 5.96B | 4.86B |
| Cost of Revenue | 8.70B | 8.65B | 8.22B | 7.60B | 6.55B | 5.75B | 5.28B | 5.12B | 4.54B | 4.61B | 4.07B | 3.33B | 2.55B |
| Gross Profit | 6.98B | 7.04B | 5.91B | 4.99B | 4.58B | 4.59B | 4.32B | 3.69B | 3.41B | 3.12B | 2.96B | 2.63B | 2.31B |
| Gross Profit Ratio | 44.51% | 44.88% | 41.81% | 39.61% | 41.14% | 44.39% | 45.02% | 41.85% | 42.88% | 40.32% | 42.08% | 44.15% | 47.54% |
| Research & Development | 41.31M | 44.40M | 40.52M | 27.37M | 27.16M | 29.21M | 29.91M | 32.69M | 29.11M | 24.60M | 15.49M | 9.57M | 6.66M |
| General & Administrative | 2.44B | 2.56B | 2.26B | 1.98B | 1.95B | 1.85B | 1.69B | 1.50B | 1.38B | 1.30B | 1.16B | 1.06B | 856.69M |
| Selling & Marketing | 1.58B | 1.63B | 1.35B | 1.19B | 1.15B | 1.31B | 1.18B | 1.08B | 1.22B | 1.11B | 1.02B | 875.56M | 861.87M |
| SG&A | 4.03B | 4.19B | 3.61B | 3.16B | 3.10B | 3.15B | 2.87B | 2.58B | 2.60B | 2.41B | 2.18B | 1.94B | 1.72B |
| Other Expenses | 0.00 | 120.72M | 117.23M | 107.75M | 51.34M | 101.88M | 26.68M | 17.89M | 21.97M | 20.45M | 23.14M | 57.87M | 36.51M |
| Operating Expenses | 4.07B | 4.36B | 3.77B | 3.30B | 3.18B | 3.24B | 2.96B | 2.67B | 2.72B | 2.48B | 2.24B | 1.98B | 1.76B |
| Cost & Expenses | 12.78B | 13.01B | 11.99B | 10.90B | 9.73B | 8.99B | 8.24B | 7.80B | 7.26B | 7.10B | 6.31B | 5.31B | 4.30B |
| Interest Income | 0.00 | 39.82M | 10.03M | 11.94M | 49.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.46M | 1.53M | 0.00 |
| Interest Expense | 31.25M | 28.73M | 28.28M | 72.28M | 65.15M | 33.98M | 25.80M | 22.24M | 12.54M | 17.13M | 28.23M | 25.08M | 22.90M |
| Depreciation & Amortization | 285.87M | 272.02M | 274.44M | 256.33M | 159.91M | 147.78M | 151.96M | 151.64M | 145.24M | 131.43M | 98.89M | 76.44M | 68.77M |
| EBITDA | 2.58B | 2.90B | 2.58B | 2.00B | 1.53B | 1.59B | 1.48B | 1.11B | 985.78M | 785.69M | 845.70M | 798.28M | 657.35M |
| EBITDA Ratio | 16.44% | 19.09% | 17.34% | 15.26% | 14.25% | 15.41% | 15.96% | 13.42% | 10.77% | 10.16% | 12.02% | 13.20% | 13.56% |
| Operating Income | 2.90B | 2.72B | 2.18B | 1.67B | 1.43B | 1.45B | 1.38B | 1.03B | 710.52M | 654.26M | 746.82M | 711.18M | 589.59M |
| Operating Income Ratio | 18.52% | 17.35% | 15.40% | 13.23% | 12.82% | 13.98% | 14.38% | 11.69% | 8.94% | 8.46% | 10.62% | 11.92% | 12.14% |
| Total Other Income/Expenses | -642.65M | -86.25M | 135.44M | -64.13M | -103.47M | -36.69M | -57.10M | -79.98M | 139.45M | -14.28M | 12.63M | -12.88M | -23.92M |
| Income Before Tax | 2.26B | 2.59B | 2.28B | 1.62B | 1.30B | 1.41B | 1.30B | 932.66M | 827.99M | 638.14M | 757.42M | 698.30M | 565.68M |
| Income Before Tax Ratio | 14.42% | 16.54% | 16.11% | 12.89% | 11.67% | 13.62% | 13.53% | 10.59% | 10.42% | 8.26% | 10.77% | 11.71% | 11.65% |
| Income Tax Expense | 269.06M | 354.63M | 336.02M | 234.33M | 160.03M | 202.75M | 185.79M | 137.72M | 132.25M | 90.29M | 133.39M | 141.19M | 107.39M |
| Net Income | 1.99B | 2.24B | 1.95B | 1.39B | 1.14B | 1.21B | 1.11B | 794.91M | 695.75M | 547.88M | 624.02M | 555.60M | 455.89M |
| Net Income Ratio | 12.71% | 14.29% | 13.77% | 11.06% | 10.23% | 11.66% | 11.59% | 9.02% | 8.76% | 7.09% | 8.87% | 9.31% | 9.39% |
| EPS | 2.29 | 2.57 | 2.23 | 1.60 | 1.31 | 1.39 | 1.29 | 0.92 | 0.80 | 0.63 | 0.84 | 0.79 | 0.62 |
| EPS Diluted | 2.29 | 2.57 | 2.23 | 1.60 | 1.31 | 1.39 | 1.28 | 0.92 | 0.80 | 0.63 | 0.84 | 0.79 | 0.62 |
| Weighted Avg Shares Out | 871.87M | 871.87M | 871.87M | 871.87M | 870.85M | 865.27M | 865.25M | 865.25M | 865.25M | 865.25M | 746.78M | 728.13M | 730.12M |
| Weighted Avg Shares Out (Dil) | 871.87M | 871.87M | 871.87M | 871.87M | 870.85M | 869.04M | 868.24M | 867.54M | 865.25M | 865.25M | 746.78M | 728.13M | 730.12M |
Source: https://incomestatements.info
Category: Stock Reports